Product Description
Belcesiran is being developed by Dicerna for the treatment of Alpha-1 Antitrypsin-Deficiency Associated Liver Disease. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04764448?term=Belcesiran&draw=2&rank=2)
Mechanisms of Action: A1P Modulator
Novel Mechanism: Yes
Modality: Nucleic Acid
Route of Administration: Subcutaneous
FDA Designation: Orphan Drug - alpha 1-Antitrypsin Deficiency *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Novo Nordisk
Company Location: BAGSVAERD DENMARK G7 00000
Company CEO: Lars Fruergaard Jorgensen
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: alpha 1-Antitrypsin Deficiency
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2020-003313-35 | P2 |
Active, not recruiting |
alpha 1-Antitrypsin Deficiency |
2027-03-18 |